Fundz

Remedy Plan, Inc. reported raising $5.2 Million in an initial SEC Form D filing, from an offering of $7.2 Million

PRIVATEDec 02, 2019$5.2M of $7.2M raised

Amount Raised

$5.2 Million

$5.2 Million sold, per SEC Form D (first sale Dec 2, 2019)

Round Type

Venture

GaithersburgBiotechnologyHealthcare

Who else raised in Healthcare and Biotechnology around the same time

Companies in the same sectors as Remedy Plan that raised within 45 days of this round, from Fundz verified event records.

  • Damora Therapeutics, Inc. raised $79M on January 16, 2020.
  • Zevra Therapeutics, Inc. raised $3M (Seed) on January 13, 2020.
  • Starton Therapeutics raised $2M (Seed) on January 13, 2020.
  • Bigfoot Biomedical, Inc. raised $46M on January 13, 2020.
  • ORTHALIGN INC raised $3.2M (Seed) on January 9, 2020.
  • Jade Biosciences raised $2.5M (Seed) on January 8, 2020.

Who to call at Remedy Plan, and when

A new round usually means Remedy Plan is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Remedy Plan raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Remedy Plan, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Remedy Plan. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Remedy Plan

Location

704 Quince Orchard Rd, Ste 220

Gaithersburg, Maryland, United States

About

Remedy Plan Therapeutics is a privately-held, clinical-stage pharmaceutical company developing novel, hyperbolic NAMPT inhibitors. NAMPT is an enzyme that controls how cells use energy and is core to human biology. It is dysregulated in more than 20 diseases spanning oncology, autoimmunity, and metabolic disorders. Previous efforts by others to inhibit NAMPT activity resulted in severe on-target toxicities in healthy tissues, which prevented meaningful clinical activity. Remedy Plan has developed a first-in-class approach to NAMPT inhibition that never fully turns NAMPT activity off. This selectively avoids on-target toxicity in healthy tissues while still meaningfully inhibiting NAMPT activity in diseased cells.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Remedy Plan raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsGregory C., Executive Officer, DirectorSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Remedy Plan's next move

See what Strategic adds

Remedy Plan raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.